Ticker

IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) was the target of a significant drop in short interest in February. As of February 13th, there was short interest totaling 4,262,939 shares, a drop of 20.9% from the January 29th total of 5,390,908 shares. Approximately 6.1% of the company's stock are sold short. Based on an

IO Biotech, Inc. (IOBT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totaling 3,083,794 shares, an increase of 47.2% from the December 31st total of 2,094,316 shares. Currently, 4.4% of the company's shares are sold short.

Raymond James engaged as financial advisor Reduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James & Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously…

NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that the company intends to explore a range of strategic alternatives to maximize stockholder value. Strategic alternatives that may be evaluated include, but are not limited to, a merger, a business…